Andreas Schwarzer
Leipzig University
25 Papers
61 Citations
Andreas Schwarzer is an academic researcher from Leipzig University. The author has contributed to research in topics: Multiple myeloma & Bendamustine. The author has an hindex of 9, co-authored 20 publications.
Chat about Author
Papers
Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem‐cell transplantation or conventional chemotherapy: results of a Phase I clinical trial
Wolfram Pönisch,Marta Rozanski,Hartmut Goldschmidt,Franz Albert Hoffmann,Thomas Boldt,Andreas Schwarzer,Ute Ritter,Robert Rohrberg,Elke Schwalbe,Jens Uhlig,Thomas Zehrfeld,Veronika Schirmer,Antje Haas,Ute Kreibich,Dietger Niederwieser +14 more
TL;DR: BPT therapy was well tolerated in patients with relapsed or refractory MM, with a response rate higher than 80%.
86
Successful treatment of patients with newly diagnosed/untreated multiple myeloma and advanced renal failure using bortezomib in combination with bendamustine and prednisone
Wolfram Pönisch,Marc Andrea,Ina Wagner,Doreen Hammerschmidt,Ute Kreibich,Andreas Schwarzer,Thomas Zehrfeld,Maik Schwarz,Cornelia Winkelmann,Sirak Petros,Anette Bachmann,Tom H. Lindner,Dietger Niederwieser +12 more
TL;DR: The combination of bortezomib, bendamustine, and prednisone is effective and well tolerated in patients with a newly diagnosed multiple myeloma and renal failure.
46
Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma
Wolfram Pönisch,Malvina Bourgeois,Barbara Moll,Simone Heyn,Nadja Jäkel,Ina Wagner,Robert Rohrberg,Hans-Jürgen Hurtz,Marion Schmalfeld,Michael Aßmann,Thomas Edelmann,Martin Mohren,Franz Albert Hoffmann,Cornelia Becker,Andreas Schwarzer,Uta Schönfelder,Thomas Zehrfeld,Gerald Hensel,Kerstin Löschcke,Rainer Krahl,Haifa Al Ali,Dietger Niederwieser +21 more
TL;DR: The combination of bortezomib, bendamustine and prednisone is well tolerated in patients with relapsed or refractory MM, and the regimen was well tolerated with few significant side effects in patients without severe hematological toxicities due to previous treatments.
40
Lenalidomide, bendamustine and prednisolone exhibits a favourable safety and efficacy profile in relapsed or refractory multiple myeloma: final results of a phase 1 clinical trial OSHO - #077.
Wolfram Pönisch,Simone Heyn,Juliane Beck,Ina Wagner,Martin Mohren,Franz Albert Hoffmann,Thoralf Lange,Marion Schmalfeld,Thomas Zehrfeld,Andreas Schwarzer,Cornelia Winkelmann,Thomas Edelmann,Ramona Röhrborn,Karin Hebenstreit,Haifa Kathrin Al-Ali,Nadja Jäkel,Dietger Niederwieser +16 more
TL;DR: RBP with lenalidomide 25 mg/d, days 1–21 and bendamustine 75 mg/m2 days 1-2 is well tolerated in patients with relapsed/refractory MM.
33
Desired and perceived participation in medical decision-making in patients with haemato-oncological diseases
Jochen Ernst,Elmar Brähler,Ali Aldaoud,Andreas Schwarzer,Dietger Niederwieser,Luisa Mantovani-Löffler,Christina Schröder +6 more
TL;DR: The majority of patients with haemato-oncological illnesses desired more a passive role, which is a considerably higher portion than with solid cancer cases, and nearly every second person interviewed was included - mostly passively - in decisions in accordance with his preferences.
20